Kazuhiro Hatano

President & CEO, Linical

Kazuhiro Hatano

Message

Together with our employees, who have faced many changes and challenges and grown continuously, our company has expanded at a remarkable speed. We have breadth and depth of experience especially in difficult areas such as oncology, central nervous system (CNS) and immunology. With a high degree of specialization and professional knowledge, we have strived together as a company, day-in day-out, on developing drugs for numerous cancers, CNS diseases such as Alzheimer’s disease, as well as rare and intractable diseases for which there are no established treatment methods as yet. In recent years, “international joint clinical trial” projects, conducted simultaneously in multiple regions around the world, have made up a growing proportion of the work we do, so we have aimed at creating a strong organization capable of swiftly and reliably meeting all kinds of needs, fully utilizing the Linical Group’s global network. One of our strengths is our ability to deliver “Japan quality” services in multiple languages by our talented employees with extraordinary communication skills, located not only in Japan but in various other countries where we operate. To get new drugs approved as soon as possible, it is very important to ensure that clinical trial plans are as efficient and optimized as possible, and we actively propose the best methods across the entire process, from planning to approval. What drives us is our desire to help people everywhere to live healthier and richer lives by supporting pharmaceutical product development — in whatever small way we can.